Shares of AstraZeneca plc (LON:AZN) have been given a consensus rating of “Hold” by the twenty-one research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 4,832.56 ($62.93).
Several equities analysts recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating and issued a GBX 5,600 ($72.93) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.07) target price on AstraZeneca plc and gave the stock a “neutral” rating in a report on Tuesday, June 27th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Barclays PLC restated an “overweight” rating and set a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Monday, June 5th.
Shares of AstraZeneca plc (LON AZN) traded down 0.96% during mid-day trading on Friday, hitting GBX 4384.00. 1,583,746 shares of the company were exchanged. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s market cap is GBX 55.50 billion. The stock’s 50-day moving average price is GBX 4,945.31 and its 200 day moving average price is GBX 4,856.38.
The business also recently declared a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be paid a GBX 68.90 ($0.90) dividend. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.